Moore M - Search Results

1

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF. Templeton AJ, et al. Among authors: moore m. Ann Oncol. 2013 Dec;24(12):2972-7. doi: 10.1093/annonc/mdt397. Epub 2013 Oct 14. Ann Oncol. 2013. PMID: 24126362 Free article.

2

How American oncologists treat breast cancer: an assessment of the influence of clinical trials.

Belanger D, Moore M, Tannock I. Belanger D, et al. Among authors: moore m. J Clin Oncol. 1991 Jan;9(1):7-16. doi: 10.1200/JCO.1991.9.1.7. J Clin Oncol. 1991. PMID: 1985172

3

Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues?

Moore MJ, O'Sullivan B, Tannock IF. Moore MJ, et al. Br J Cancer. 1990 Dec;62(6):988-91. doi: 10.1038/bjc.1990.422. Br J Cancer. 1990. PMID: 2257231 Free PMC article.

4

How expert physicians would wish to be treated if they had genitourinary cancer.

Moore MJ, O'Sullivan B, Tannock IF. Moore MJ, et al. J Clin Oncol. 1988 Nov;6(11):1736-45. doi: 10.1200/JCO.1988.6.11.1736. J Clin Oncol. 1988. PMID: 3054004 Clinical Trial.

5

Quality assessment of clinical trials in bladder cancer.

Tannock I, Moore M. Tannock I, et al. Among authors: moore m. Eur Urol. 1988;14 Suppl 1:46. doi: 10.1159/000473045. Eur Urol. 1988. PMID: 3181246 No abstract available.

6

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Moore MJ, et al. J Clin Oncol. 1994 Apr;12(4):689-94. doi: 10.1200/JCO.1994.12.4.689. J Clin Oncol. 1994. PMID: 7512127 Clinical Trial.

7

Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

Mertens WC, Eisenhauer EA, Jolivet J, Ernst S, Moore M, Muldal A. Mertens WC, et al. Among authors: moore m. Ann Oncol. 1994 Feb;5(2):185-7. doi: 10.1093/oxfordjournals.annonc.a058776. Ann Oncol. 1994. PMID: 7910480 Free article. Clinical Trial.

8

A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.

Moore MJ, Iscoe N, Tannock IF. Moore MJ, et al. J Urol. 1993 Oct;150(4):1131-4. doi: 10.1016/s0022-5347(17)35706-3. J Urol. 1993. PMID: 8371371 Clinical Trial.

9

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Tannock IF, et al. Among authors: moore mj. J Clin Oncol. 1996 Jun;14(6):1756-64. doi: 10.1200/JCO.1996.14.6.1756. J Clin Oncol. 1996. PMID: 8656243 Clinical Trial.

10

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against.

Jewett MA, Khakpour G, Moore MJ. Jewett MA, et al. Among authors: moore mj. Eur Urol. 1996;29 Suppl 2:45-8. doi: 10.1159/000473839. Eur Urol. 1996. PMID: 8717463 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,504 results

Search Page

Filters